Yasui H, Butscher W, Cohen M, Spriggs N, Wersto R, Kohn E C, Liotta L, Gardner K
Laboratory of Pathology, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Biol Chem. 1997 Nov 7;272(45):28762-70. doi: 10.1074/jbc.272.45.28762.
Carboxyamidotriazole (CAI) is a calcium influx inhibitor that has both antiproliferative and antimetastatic activities. Pretreatment of human T-cells with micromolar concentrations of CAI causes a near complete inhibition of calcium-regulated mitogen-induced transcription from the human immunodeficiency virus (HIV) long terminal repeat (LTR). This inhibition is selective since other mitogen-activated gene regulatory elements, such as the 12-O-tetradecanoylphorbol-13-acetate response element, are not influenced by the drug. HIV LTR transcription inhibition is maximal at 1.0 microM CAI, requires a pretreatment interval of at least 8 h for optimum inhibition, and shows no acute interference with the growth properties of the cells. Moreover, the inhibition is rapidly reversible upon removal of the drug from the medium. Studies to identify enhancer elements within the HIV LTR that are functionally sensitive to low-dose long-term pretreatment with CAI indicate that the NF-kappaB-binding sites are among the major targets of drug action. In vitro DNA binding studies with nuclear extracts prepared from mitogen-induced T-cells stimulated in the presence of CAI indicate that the drug differentially influences the calcium-regulated downstream signal transduction pathways necessary for specific NF-kappaB DNA binding activity at the two kappaB sites within the HIV LTR. Studies with ionomycin and thapsigargin show that repression is specific for selected modes of inducible calcium entry and indicate that, in T-cells, a major mechanism of CAI action is to modulate calcium influx at a level that is proximal to the regulated release of calcium from intracellular stores. Measurement of calcium influx in CAI-treated cells reveals a dramatic and reversible inhibition of mitogen-induced calcium influx. These results indicate that CAI can be an important and effective pharmacological tool for analysis of the calcium-dependent modulation of HIV LTR transcription.
羧酰胺三唑(CAI)是一种钙内流抑制剂,具有抗增殖和抗转移活性。用微摩尔浓度的CAI预处理人T细胞会导致人免疫缺陷病毒(HIV)长末端重复序列(LTR)的钙调节丝裂原诱导转录几乎完全受到抑制。这种抑制具有选择性,因为其他丝裂原激活的基因调控元件,如12-O-十四烷酰佛波醇-13-乙酸酯反应元件,不受该药物影响。HIV LTR转录抑制在1.0 microM CAI时最大,需要至少8小时的预处理间隔才能达到最佳抑制效果,并且对细胞的生长特性没有急性干扰。此外,从培养基中去除药物后,抑制作用可迅速逆转。鉴定HIV LTR中对低剂量长期CAI预处理功能敏感的增强子元件的研究表明,NF-κB结合位点是药物作用的主要靶点之一。用从在CAI存在下刺激的丝裂原诱导的T细胞制备的核提取物进行的体外DNA结合研究表明,该药物对HIV LTR内两个κB位点特异性NF-κB DNA结合活性所需的钙调节下游信号转导途径有不同影响。用离子霉素和毒胡萝卜素进行的研究表明,抑制作用对特定的诱导性钙内流模式具有特异性,并表明在T细胞中,CAI作用的主要机制是在靠近细胞内钙库调节性释放的水平上调节钙内流。测量CAI处理细胞中的钙内流揭示了丝裂原诱导的钙内流的显著且可逆的抑制。这些结果表明,CAI可以成为分析HIV LTR转录的钙依赖性调节的重要且有效的药理学工具。